Smithkline Beecham Corporation

Other

The Johns Hopkins University

James David Winkler

Floyd Harold Chilton, Iii

Connie L Erickson-Miller

Stephen Dudley Holmes

Deirdre M Hickey

Lisa A Marshall

Floyd H Chilton

Ruth Judik Mayer

James S Dixon

Jerry Leroy Adams

William Edward Bondinell

Ralph F Hall

Margaret E Sorenson

Ravi Shanker Garigipati

Jeffrey Richard Jackson

Raplh F Hall

A method of inhibiting or reducing cell proliferation in a human or mammal is disclosed. This method involves administering to a human or mammal an effective amount of CoA-independent transacylase inhibiting amount of a compound of the formula disclosed in the specification.

Beta lactams as antiproliferative agents

Tie2 receptor antagonist antibodies, their use in inhibiting angiogenesis and other uses are disclosed.

Tie2 antagonist antibodies

The present invention is to the novel use of a cytokine inhibitor, which cytokine is inhibited by the inhibition of the kinase CSBP/p38/RK, for the treatment of chronic diseases which are caused by excessive, undesired or inappropriate angiogenesis.

Use of CSAID&trade; compounds as inhibitors of angiogenesis

Tie2 receptor agonist antibodies, their use in enhancing angiogenesis and other uses are disclosed.

Tie2 agonist antibodies

This invention relates to methods for treating diseases or disorders mediated by lipid inflammatory mediators, arachidonic acid, its metabolites and/or platelet activating factor (PAF), which method comprises administration to a mammal in need thereof of an effective Coenzyme A independent transacylase (CoA-IT) inhibiting amount of a triphenylmethylazetidinone. This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a triphenylmethylazetidinone.

Beta-lactam inhibitors of CoA-IT

Anti-inflammatory compounds

Inhibition of inflammatory lipid mediators

Coenzyme A-independent transacylase is required for the release of free arachidonic acid, and the production of arachidonic acid metabolites and platelet activation factor. Blocking of this enzyme inhibits the production of these inflammatory mediators and will be of therapeutic utility in a broad range of allergic and inflammatory diseases and disorders. Compounds are described herein which inhibit the action of CoA-IT and are therefore useful in the treatment of disease states caused thereby.

CoA-IT and PAF inhibitors

This invention relates to the novel compounds and pharmaceutical compositions of Formulas (I) and (II). This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).

This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier. This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).

Growing community of inventors

Fort Washington, PA, United States of America

James David Winkler